ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NCI May Seek Cuts In R01s, P01s If Congress Approves Rescission

January 30, 1981

President Proposes 2.1% Incerase for NIH, 2.4% Increase for NCI, In Year 2000 Budget

February 5, 1999

In Brief: FDA To Review Preclinical Testing, Phase I Protocols At Open Advisory Group Meeting

November 14, 1975

Americans Shouldn’t Take NIH for Granted, Healy Tells NCAB

May 24, 1991

Bills Would Give FDA Authority to Approve Generic Biotech Drugs.

February 16, 2007

Cancer Program Advocates Seek $170 Mil. Above President’s Budget, Vow To Close Bypass Gap

May 8, 1992